Anaptys Bio (NASDAQ:ANAB) stock plunged 33% Wednesday after the company said it was scrapping further development of its drug candidate ANB032 due to disappointing clinical results.

ANB032 failed to meet primary and secondary endpoints in a Phase 2 trial for moderate-to-severe atopic dermatitis (AD). AnaptysBio will shift resources to autoimmune programs with key trial data ...

ANB032 was well tolerated with no safety signals observed. “While ANB032 was safe and well tolerated, we’re disappointed by these efficacy results in AD and will discontinue further investment ...

AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a ...

The ARISE-AD trial enrolled 201 patients to test ANB032, an antibody designed to target B- and T-lymphocyte attenuator (BTLA) protein to stymie immune cells and reduce inflammation. By week 14 of ...

Shares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist ...

ANB032 was well tolerated across all doses with no safety signals observed AD trial and all further investment in ANB032 will be discontinued Anticipate top-line Phase 2b data in rheumatoid arthritis ...

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data On Wednesday, AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the ...

ANB032 was well tolerated across all doses with no safety signals observed AD trial and all further investment in ANB032 will be discontinued Anticipate top-line Phase 2b data in rheumatoid ...

Morningstar brands and products Company Portfolio ...